Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study.
Jonathan Q TrinhCassaundra AcostaArti EaswarRobert GalamagaAlan TanPublished in: Cancer reports (Hoboken, N.J.) (2023)
Dual checkpoint inhibition deserves consideration when treating metastatic SNUC, especially after single agent therapy has failed. The positive effect of this treatment may be augmented by IDO1 inhibition.